Last reviewed · How we verify

NCT04713267: ISABel

ISABel: Intelligent Sleep Apnoea Bed

Terminated NA Last updated 28 February 2022
What this trial tests

NA trial testing ISABel Bed 1 in Effect of ISABel Bed 1 Ans ISABel Bed 2 in 10 participants. Terminated before completion.

Timeline
19 February 2021
Primary endpoint
24 January 2022
24 January 2022

Quick facts

Lead sponsorSwiss Federal Institute of Technology
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsequential
Maskingnone
Primary purposedevice feasibility
Enrollment10
Start date19 February 2021
Primary completion24 January 2022
Estimated completion24 January 2022
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

Swiss Federal Institute of Technology

Who can join

Adults 18 to 80, any sex, with Effect of ISABel Bed 1 Ans ISABel Bed 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this trial is to assess the effect of two automated beds on severity of POSA as well as the feasibility of these beds as POSA treatment. These beds are equipped with sensors detecting apnoeas and hypopnoeas from physiological measurements - such as chest movement or breathing sound -, and coherently reacting by actively changing the user position whenever an apnoeic event occurs. Thereby we will investigate a possible treatment alternative to already established OSA therapies, either as a valuable add-on for patients eligible to the currently available therapies or as primary treatment option.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Swiss Federal Institute of Technology trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04713267.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing